By USFDA
Alembic Pharmaceuticals announced that the Company's Bioequivalence facility located at Baroda was inspected by US Food & Drug Administration (FDA) between 6 March 2017 & 10 March 2017, between 13 March 2017 & 17 March 2017 and between 10 April 2017 to 12 April 2017 for a) Bioequivalence Clinical b) Bioequivalence Bioanalytical c) Pharmacovigilance There were no 483s issued by US FDA at the end of the inspection.Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
